NASDAQ:SNGX Soligenix (SNGX) Stock Forecast, Price & News $0.72 -0.01 (-0.95%) (As of 11:18 AM ET) Add Compare Share Share Today's Range$0.71▼$0.7450-Day Range$0.71▼$2.2952-Week Range$0.65▼$15.00Volume102,287 shsAverage Volume547,798 shsMarket Capitalization$2.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Soligenix MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.55) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Soligenix. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.37% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 62.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNGX. Previous Next 3.8 News and Social Media Coverage News SentimentSoligenix has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Soligenix this week, compared to 2 articles on an average week.Search Interest32 people have searched for SNGX on MarketBeat in the last 30 days. This is an increase of 967% compared to the previous 30 days.MarketBeat Follows2 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.99% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 7.17% of the stock of Soligenix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soligenix are expected to grow in the coming year, from ($5.55) to ($3.06) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Soligenix (NASDAQ:SNGX) StockSoligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.Read More Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Stock News HeadlinesMay 30, 2023 | finance.yahoo.comSNGX: Positive Results for Compatibility Study of HyBryte in CTCLMay 16, 2023 | finanznachrichten.deSoligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 16, 2023 | finance.yahoo.comSoligenix Announces European Patent Grant for Use of Dusquetide in Oral MucositisMay 15, 2023 | finance.yahoo.comSoligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaMay 9, 2023 | finance.yahoo.comSoligenix Announces Closing of $8.5 Million Public OfferingMay 5, 2023 | finance.yahoo.comSoligenix Announces Pricing of $8.5 Million Public OfferingMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 4, 2023 | finance.yahoo.comWhy Are Soligenix Shares Trading Higher TodayMay 3, 2023 | finance.yahoo.comSoligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of DirectorsMay 1, 2023 | finance.yahoo.comSoligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's DiseaseApril 24, 2023 | finance.yahoo.comSNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…April 24, 2023 | finance.yahoo.comSoligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaApril 14, 2023 | msn.comSoligenix Shares Tumble as FDA Demands More DataApril 14, 2023 | msn.comSoligenix stock sinks as FDA seeks additional positive results for cancer drugApril 14, 2023 | finance.yahoo.comSoligenix Provides Regulatory Update on HyBryte™April 5, 2023 | finance.yahoo.comSoligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302April 5, 2023 | americanbankingnews.comSoligenix, Inc. Expected to Earn Q1 2023 Earnings of ($1.25) Per Share (NASDAQ:SNGX)April 3, 2023 | finance.yahoo.comSNGX: Meeting with FDA to Discuss Refusal to File Letter…April 3, 2023 | finance.yahoo.comSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaMarch 31, 2023 | finance.yahoo.comSoligenix Announces Recent Accomplishments And Year-End 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comSoligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus OutbreaksFebruary 14, 2023 | investorplace.comWhy Is Soligenix (SNGX) Stock Down 27% Today?February 14, 2023 | investorplace.comWhy Is Soligenix (SNGX) Stock Down 35% Today?February 14, 2023 | prnewswire.comSoligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaFebruary 9, 2023 | finance.yahoo.comSoligenix Announces Reverse Stock SplitSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Company Calendar Last Earnings11/12/2021Today5/31/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees13Year Founded1987Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,800,000.00 Net Margins-996.96% Pretax Margin-1,218.01% Return on Equity-589.84% Return on Assets-64.89% Debt Debt-to-Equity Ratio6.67 Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual Sales$950,000.00 Price / Sales2.27 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-0.63Miscellaneous Outstanding Shares2,980,000Free Float2,857,000Market Cap$2.15 million OptionableNot Optionable Beta1.74 Social Links Key ExecutivesChristopher J. SchaberChairman, President & Chief Executive OfficerJonathan L. GuarinoChief Financial Officer, Secretary & Senior VPOreola DoniniChief Scientific Officer & Senior Vice PresidentRichard C. StraubeChief Medical Officer & Senior Vice PresidentAdam T. RumageVP-Regulatory Affairs & Project ManagementKey CompetitorsContraFectNASDAQ:CFRXOncoSec MedicalNASDAQ:ONCSSciSparcNASDAQ:SPRCAyala PharmaceuticalsNASDAQ:ADXSGRI BioNASDAQ:GRIView All CompetitorsInstitutional OwnershipFirst Wilshire Securities Management Inc.Sold 326,666 shares on 5/16/2023Ownership: 0.784%Geode Capital Management LLCSold 303,058 shares on 5/16/2023Ownership: 0.728%View All Institutional Transactions SNGX Stock - Frequently Asked Questions How have SNGX shares performed in 2023? Soligenix's stock was trading at $0.4520 at the beginning of 2023. Since then, SNGX shares have increased by 59.8% and is now trading at $0.7223. View the best growth stocks for 2023 here. Are investors shorting Soligenix? Soligenix saw a increase in short interest in May. As of May 15th, there was short interest totaling 350,100 shares, an increase of 63.0% from the April 30th total of 214,800 shares. Based on an average daily volume of 835,000 shares, the short-interest ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are sold short. View Soligenix's Short Interest. When is Soligenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our SNGX earnings forecast. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The biopharmaceutical company earned $0.19 million during the quarter, compared to analysts' expectations of $0.80 million. Soligenix had a negative trailing twelve-month return on equity of 589.84% and a negative net margin of 996.96%. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM). What is Soligenix's stock symbol? Soligenix trades on the NASDAQ under the ticker symbol "SNGX." Who are Soligenix's major shareholders? Soligenix's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Wilshire Securities Management Inc. (0.78%) and Geode Capital Management LLC (0.73%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube. View institutional ownership trends. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Soligenix's stock price today? One share of SNGX stock can currently be purchased for approximately $0.72. How much money does Soligenix make? Soligenix (NASDAQ:SNGX) has a market capitalization of $2.15 million and generates $950,000.00 in revenue each year. How can I contact Soligenix? Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467. This page (NASDAQ:SNGX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.